AskBio details Phase 2 GenePHIT baseline data

Gene therapy vial in a clinical lab illustrating Phase 2 baseline data for experimental treatment

Key Points

01AskBio shared baseline data from the Phase 2 GenePHIT trial at ESC Congress
02GenePHIT evaluates one-time intracoronary gene therapy AB-1002 in non-ischemic HFrEF
03Baseline characteristics show a high burden of comorbidities and device use
04Initial efficacy and safety results from GenePHIT are expected in H1 2027

AskBio outlines Phase 2 GenePHIT trial at ESC Congress

AskBio presented new baseline participant data from GenePHIT, a randomized, double‑blind, placebo‑controlled Phase 2 trial of umiposgene parvec (AB‑1002), at the European Society of Cardiology Congress. The study is designed to evaluate a potential one‑time gene therapy for adults with non‑ischemic heart failure with reduced ejection fraction who are already receiving guideline‑directed medical therapy.

The company reported that GenePHIT has completed enrollment and randomization, with more than 170 participants included in the trial. Study sites span multiple countries, reflecting a broad, international recruitment effort for this mid‑stage heart failure gene therapy program.

Design and administration of umiposgene parvec

GenePHIT is structured to assess the efficacy, safety and tolerability of umiposgene parvec when delivered as a single administration. The investigational product is infused via antegrade intracoronary delivery using a standard catheter, and the protocol does not include immune suppression for this procedure.

As a randomized, double‑blind, placebo‑controlled trial, GenePHIT is positioned to compare outcomes between patients receiving the gene therapy and those given placebo. The multicenter design supports collection of data across diverse clinical settings and healthcare systems.

Baseline patient profile shows high disease burden

Baseline characteristics presented from GenePHIT describe a population with substantial heart failure burden. Participants have non‑ischemic heart failure with reduced ejection fraction and are being treated with guideline‑directed medical therapy.

Nearly half of enrolled participants have a history of atrial fibrillation, and roughly 45% have an implantable cardioverter‑defibrillator. These data indicate that many patients in the trial have advanced disease features and are already using device‑based therapies in addition to medications.

Timeline and regulatory status

Initial efficacy and safety outcomes from GenePHIT are expected in the first half of 2027. These future readouts are intended to provide insight into whether a single intracoronary administration of umiposgene parvec can improve outcomes in this high‑risk heart failure population.

AskBio emphasized that umiposgene parvec remains an investigational therapy. It has not been approved by any regulatory authority, and its safety and efficacy have not yet been established outside of ongoing clinical research.

Key Takeaways

01GenePHIT has advanced to a key milestone with enrollment and randomization completed, setting the stage for mid‑term efficacy and safety data in 2027.
02The trial targets a non‑ischemic HFrEF population already on guideline‑directed therapy, indicating that the gene therapy is being tested in patients with significant residual disease burden.
03Delivery via a one‑time antegrade intracoronary infusion without immune suppression differentiates umiposgene parvec from many other advanced therapies now in development.
04The high prevalence of atrial fibrillation and ICD use in GenePHIT participants underscores the clinical need for new options beyond current drugs and devices.
05With umiposgene parvec still investigational and unapproved, forthcoming Phase 2 results will be central to determining its future clinical and regulatory path.

References